Veru to Report Fiscal Year 2025 Financial Results on December 17th
AI Sentiment
Positive
7/10
as of 12-12-2025 3:31pm EST
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
Upcoming Earnings Alert:
Get ready for potential market movements as Veru Inc. (VERU) prepares to release earnings report on 17 Dec 2025.
| Founded: | 1971 | Country: | United States |
| Employees: | N/A | City: | MIAMI |
| Market Cap: | 39.8M | IPO Year: | 1990 |
| Target Price: | $25.00 | AVG Volume (30 days): | 108.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.11 - $14.20 | Next Earning Date: | 12-17-2025 |
| Revenue: | $16,886,419 | Revenue Growth: | 337.24% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
VERU Breaking Stock News: Dive into VERU Ticker-Specific Updates for Smart Investing
AI Sentiment
Positive
7/10
See how VERU stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "VERU Veru Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.